Streetbeat News

Revenues

BASE

Couchbase has revised its Q2 2024 revenue guidance to $41.2M-$41.8M, lower than the previous estimate of $43.31M.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 8:19 pm

BASE

Couchbase expects Q2 revenue to be between $41.2M and $41.8M, lower than the estimated $43.31M.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 8:17 pm

CVGW

Calavo Growers (CVGW) expects avocado volumes in the fiscal second half to exceed prior year levels, indicating a potential increase in revenues.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 8:12 pm

SLGC

SomaLogic reaffirms its 2023 revenue expectations of $80M-$84M, in line with the consensus estimate of $81.62M.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 8:08 pm

FSR

Fisker announced it will begin US deliveries of its all-electric Fisker Ocean SUV later this month and has agreed to sell emission credits to a major automaker at competitive rates.

Portfolio Pulse from Charles Gross

June 06, 2023 | 7:40 pm

CSTL

Canaccord Genuity maintains a Buy rating on Castle Biosciences Inc (NASDAQ:CSTL) but lowers the price target from $60 to $40 due to lower DecisionDxSCC revenue and an increased discount rate. Novitas has stated that Castle's DecisionDx-SCC and DecisionDx-Melanoma do not meet the criteria for coverage, but the company is working on a solution.

Portfolio Pulse from Vandana Singh

June 06, 2023 | 7:28 pm

SST

SST shares are trading higher after the company reported better-than-expected Q4 revenue results.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 7:20 pm

HQY

KeyBanc Capital Markets analyst Scott Schoenhaus reiterated an Overweight rating on HealthEquity, Inc. (NASDAQ:HQY) with an $85 price target. HealthEquity delivered better-than-expected Q1 earnings and revenues, and raised its FY24 revenue and Adj. EBITDA guidance. The analyst believes the company is well-positioned to grow revenue in the Health Savings Accounts markets and has a strong cash position.

Portfolio Pulse from Nabaparna Bhattacharya

June 06, 2023 | 6:59 pm

NVRO

Oppenheimer analyst Suraj Kalia has reiterated an Outperform rating on Nevro Corp. (NYSE:NVRO) with a price target of $40, despite lowering FY23 and FY24 revenue and EPS estimates due to uncertainties in the company's core business. Nevro's 2Q revenue guidance was also reduced to $106 million-$108 million.

Portfolio Pulse from Nabaparna Bhattacharya

June 06, 2023 | 6:56 pm

TSLA

Tesla shares are trading higher by 0.90% after announcing a 2.4% MoM growth in May China sales and a 141.6% YoY increase compared to May 2022. Citigroup reaffirmed a Neutral rating for the stock and increased its price target from $175 to $215.

Portfolio Pulse from Henry Khederian

June 06, 2023 | 6:11 pm